Envista Holdings Co. (NYSE:NVST) Receives $29.60 Average PT from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have received a consensus rating of “Reduce” from the eleven brokerages that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $27.90.

NVST has been the topic of several research reports. William Blair cut shares of Envista from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 8th. Morgan Stanley cut shares of Envista from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $33.00 to $21.00 in a report on Friday. Jefferies Financial Group cut shares of Envista from a “buy” rating to a “hold” rating and reduced their target price for the company from $30.00 to $23.00 in a report on Friday, February 9th. UBS Group started coverage on shares of Envista in a report on Friday, January 5th. They issued a “neutral” rating and a $26.00 target price on the stock. Finally, TheStreet cut shares of Envista from a “c” rating to a “d+” rating in a report on Wednesday, February 7th.

Envista Stock Up 1.8 %

Shares of NVST opened at $20.39 on Wednesday. The stock has a market capitalization of $3.50 billion, a PE ratio of -33.43, a P/E/G ratio of 3.79 and a beta of 1.35. Envista has a 1 year low of $18.95 and a 1 year high of $38.68. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.90 and a current ratio of 2.23. The company’s 50-day simple moving average is $20.95 and its 200-day simple moving average is $22.72.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.04). The business had revenue of $645.60 million for the quarter, compared to analyst estimates of $638.37 million. Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.52 EPS. Analysts forecast that Envista will post 1.43 earnings per share for the current fiscal year.

Institutional Trading of Envista

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nuance Investments LLC grew its position in shares of Envista by 953.8% during the fourth quarter. Nuance Investments LLC now owns 3,931,054 shares of the company’s stock worth $94,581,000 after acquiring an additional 3,558,031 shares during the last quarter. River Road Asset Management LLC purchased a new position in shares of Envista during the fourth quarter worth approximately $54,931,000. Franklin Resources Inc. grew its position in shares of Envista by 65.3% during the fourth quarter. Franklin Resources Inc. now owns 5,262,092 shares of the company’s stock worth $126,606,000 after acquiring an additional 2,077,786 shares during the last quarter. Norges Bank purchased a new position in shares of Envista during the fourth quarter worth approximately $42,874,000. Finally, Vanguard Group Inc. grew its position in shares of Envista by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 17,167,767 shares of the company’s stock worth $413,056,000 after acquiring an additional 944,596 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.